Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

Next Previous
Search
Trial Profile

A PHASE 1, OPEN-LABEL, FIXED-SEQUENCE STUDY TO ESTIMATE THE EFFECT OF PF-07081532 ADMINISTRATION ON THE SINGLE-DOSE PHARMACOKINETICS OF DABIGATRAN AND ROSUVASTATIN IN OVERWEIGHT OR OBESE ADULT PARTICIPANTS

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 17 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Lotiglipron (Primary) ; Rosuvastatin (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Pharmacokinetics
  • Sponsors Pfizer

    • Most Recent Events

    • 11 Sep 2023 Planned End Date changed from 3 Aug 2023 to 11 Sep 2023.
    • 18 Jul 2023 Planned End Date changed from 29 Sep 2023 to 3 Aug 2023.
    • 26 Jun 2023 According to a Pfizer media release, based on pharmacokinetic data from NCT05671653, NCT05788328 and laboratory measurements of elevated transaminases in NCT05579977, the company has decided to terminate the clinical development of lotiglipron.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top